Trial Profile
A Randomized Phase II Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacititdine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 05 Apr 2024
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Lenalidomide; Vorinostat
- Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 20 Aug 2017 Results published in the Journal of Clinical Oncology
- 08 Dec 2015 Primary endpoint has not been met. (Overall survival (OS) (Phase III)), as per results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology